Albonico G, Querzoli P, Ferretti S, Rinaldi R, Nenci I
Department of Experimental and Diagnostic Medicine, Ferrara University, Italy.
Cancer Detect Prev. 1998;22(4):313-8. doi: 10.1046/j.1525-1500.1998.cdoa41.x.
In 74 in situ breast cancers an immunohistochemical study for estrogen (ER) and progesterone (PR) receptors, proliferation index (PI), and c-erbB-2, p53, and bcl-2 overexpression was performed. Cases were categorized as ductal carcinoma in situ (DCIS) comedo: 24.3% of cases; DCIS non comedo: 27% of cases; DCIS cribriform: 5.4% of cases; lobular carcinoma in situ (LCIS): 16.3% of cases; mixed carcinoma in situ: 27% of cases. Quantitation of immunohistochemical results was obtained with an image analysis computerized system (CAS 200). The cutoff values used were: 10% of positive area for ER, PR, NEU, and bcl-2; 5% of positive area for p53; 13% of PI for proliferative activity. DCIS cribriform and LCIS displayed a higher positivity for ER (92.6 and 93.8% of cases); DCIS cribriform and DCIS non comedo a higher for PR (89 and 75.3%); DCIS comedo presented the highest values for PI (65.4%), NEU (72.8%), and p53 expression (37.3%). All DCIS cribriform and DCIS non comedo and 99.6% of LCIS expressed bcl-2. The results underscore the importance of biological characterization of breast carcinoma in situ with the aim to define lesions natural history.
对74例原位乳腺癌进行了雌激素（ER）和孕激素（PR）受体、增殖指数（PI）以及c-erbB-2、p53和bcl-2过表达的免疫组织化学研究。病例分类为粉刺型导管原位癌（DCIS）：占病例的24.3%；非粉刺型DCIS：占病例的27%；筛状DCIS：占病例的5.4%；小叶原位癌（LCIS）：占病例的16.3%；混合性原位癌：占病例的27%。使用图像分析计算机系统（CAS 200）获得免疫组织化学结果的定量数据。所采用的临界值为：ER、PR、NEU和bcl-2的阳性面积为10%；p53的阳性面积为5%；PI的增殖活性为13%。筛状DCIS和LCIS的ER阳性率较高（分别为92.6%和93.8%）；筛状DCIS和非粉刺型DCIS的PR阳性率较高（分别为89%和75.3%）；粉刺型DCIS的PI（65.4%）、NEU（72.8%）和p53表达（37.3%）值最高。所有筛状DCIS和非粉刺型DCIS以及99.6%的LCIS均表达bcl-2。结果强调了原位乳腺癌生物学特征的重要性，目的是确定病变的自然史。
